Zevra Therapeutics, Inc. (ZVRA)

Every figure this model derived for ZVRA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 775,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 221,570,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 251,302,000 AssetsCurrent 2026-06-30
current liabilities 48,632,000 LiabilitiesCurrent 2026-06-30
equity 217,652,000 StockholdersEquity 2026-06-30
interest expense 5,710,000 InterestExpenseNonoperating 2026-06-30
ocf 33,399,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 136,071,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 13,129,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ZVRA on one particular measure came for.

RatioValue
cash operating margin71.28
current ratio5.17
current ratio reported5.17
dilution pct23.83
fcf margin23.98
growth cv1.31
interest cover14.43
operating margin60.54
owner earnings margin14.33
revenue growth119.4
revenue growth per share77.18
roic112.19
rule of 40179.94
sbc pct revenue9.65

What to be careful about

What this model itself distrusts about ZVRA's figures. Written by the derivation as it ran, not added afterwards.